Private Wealth Partners LLC Lowers Stock Holdings in AbbVie Inc. $ABBV

Private Wealth Partners LLC trimmed its position in AbbVie Inc. (NYSE:ABBV) by 4.3% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 142,709 shares of the company’s stock after selling 6,413 shares during the period. AbbVie comprises approximately 2.3% of Private Wealth Partners LLC’s holdings, making the stock its 13th biggest holding. Private Wealth Partners LLC’s holdings in AbbVie were worth $32,608,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Diversified Trust Co raised its stake in shares of AbbVie by 23.6% during the third quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock worth $13,215,000 after acquiring an additional 10,891 shares in the last quarter. Permanent Capital Management LP purchased a new position in shares of AbbVie during the third quarter worth approximately $720,000. Railway Pension Investments Ltd raised its stake in shares of AbbVie by 33.0% during the third quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock worth $197,723,000 after acquiring an additional 211,800 shares in the last quarter. World Investment Advisors raised its stake in shares of AbbVie by 9.4% during the third quarter. World Investment Advisors now owns 113,925 shares of the company’s stock worth $26,378,000 after acquiring an additional 9,811 shares in the last quarter. Finally, Charles Schwab Trust Co raised its stake in shares of AbbVie by 93.4% during the third quarter. Charles Schwab Trust Co now owns 32,105 shares of the company’s stock worth $7,434,000 after acquiring an additional 15,502 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.06% of the company’s stock.

AbbVie Stock Down 2.1%

NYSE ABBV opened at $204.08 on Tuesday. AbbVie Inc. has a 52 week low of $168.54 and a 52 week high of $244.81. The firm has a market capitalization of $360.85 billion, a P/E ratio of 86.48, a PEG ratio of 0.74 and a beta of 0.38. The company has a 50-day moving average price of $218.62 and a 200-day moving average price of $223.14.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. During the same quarter in the prior year, the firm earned $2.16 EPS. The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities research analysts anticipate that AbbVie Inc. will post 14.26 EPS for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.4%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio is currently 293.22%.

Analyst Upgrades and Downgrades

ABBV has been the topic of several recent analyst reports. Berenberg Bank set a $275.00 target price on shares of AbbVie in a report on Tuesday, January 20th. Guggenheim lifted their price target on shares of AbbVie from $242.00 to $249.00 and gave the company a “buy” rating in a report on Friday, April 10th. Royal Bank Of Canada initiated coverage on AbbVie in a research report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price objective for the company. Evercore dropped their price target on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 4th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and issued a $223.00 target price on shares of AbbVie in a research note on Wednesday, January 28th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $253.43.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Wall Street support remains: RBC Capital maintained a Buy on ABBV with a $260 target, signaling continued analyst conviction that the shares are undervalued relative to cash flow and dividend support. AbbVie Is One Of The Major Stock To Buy According To Wall Street
• Positive Sentiment: Investor bullishness persists: a buy-side piece highlights AbbVie’s attractive yield, cash generation and buyback profile as reasons to add on pullbacks — a demand-side support for the stock. Why I Can’t Stop Buying AbbVie Stock
• Positive Sentiment: Commercial & marketing activity: AbbVie launched a cross-agency “PSO Done” psoriasis campaign to boost patient awareness and support its dermatology franchise, which could help sales momentum over time. AbbVie launches ‘PSO Done’ psoriasis campaign
• Positive Sentiment: Pipeline collaboration progress: AbbVie hit a development milestone with Nxera (US$10M payment reported), signaling external validation and advancement in its neurology research collaborations. Nxera Pharma to Receive US$10 Million Milestone Payment
• Neutral Sentiment: Community / ecosystem engagement: AbbVie is sponsoring a new BioLabs facility in Toronto — supportive for local innovation links but unlikely to move near-term fundamentals. AbbVie Sponsors New BioLabs Facility in Toronto
• Negative Sentiment: Near-term revenue pressure flagged: multiple reports point to AbbVie falling more than the broader market after investors focused on oncology headwinds — notably declining Imbruvica sales and pricing pressure — which analysts say could weigh on Q1 top-line growth and contributed to today’s share weakness. Here’s Why AbbVie (ABBV) Fell More Than Broader Market Zacks: Here’s Why AbbVie Fell
• Negative Sentiment: Analyst concerns on oncology mix: a Zacks write-up specifically warns that Imbruvica declines and pricing pressure in the oncology unit could drag Q1 revenue despite growth from newer therapies — a tangible near-term earnings risk. Will AbbVie’s Oncology Franchise Weigh on Q1 Top-line Growth?

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.